Company Grifols, S.A.

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 05:10:28 2024-12-12 am EST			5-day change	1st Jan Change
9.605 ^EUR	+8.73%		+9.27%	-38.23%

05:36am	Grifols Plans Issuance of EUR1.3 Billion Notes for Debt Repayment	MT
Dec. 10	Flat Footed Calls for Prompt Governance Overhaul at Grifols	CI

Business description: Grifols, S.A.

Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:

- products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries;

- diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;

- hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;

- other (3.1%): primarily intermediate biological products and subcontracted manufacturing services.

Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).

Number of employees: 23,000

Sales by Activity: Grifols, S.A.

Fiscal Period: December	2019	2020	2021	2022	2023
Biopharma	3.99B	4.24B	3.81B	5.01B	5.56B
Bio Supplies	267M	224M	226M	146M	160M
Diagnostic	734M	776M	779M	671M	670M
Others	22.82M	31.99M	39.62M	250M	203M
Intersegments	-52.18M	-53.11M	-67.55M	-8.95M	-
Hospital	134M	119M	141M	-	-

See all business segments

Geographical breakdown of sales: Grifols, S.A.

Fiscal Period: December	2019	2020	2021	2022	2023
United States + Canada	3.39B	3.6B	3.15B	3.86B	3.9B
Rest of World	851M	906M	872M	1.18B	1.44B
European Union (Incl. Spain)	-	-	-	-	1.26B
Spain	268M	339M	362M	321M	-
Rest of European Union	588M	495M	544M	712M	-

See all geographic segments

Managers: Grifols, S.A.

Director	Title	Age	Since
Nacho Abia CEO	Chief Executive Officer	56	2024-03-31
Albert Coma-Cros CTO	Chief Tech/Sci/R&D Officer	-	2020-12-31
Tomás Dagá Gelabert PRN	Corporate Officer/Principal	68	2016-04-30
Nuria Pascual Lapeña DFI	Director of Finance/CFO	61	1995-12-31
Montserrat Gaja Llamas HRO	Human Resources Officer	58	2021-06-30

See GRIFOLS, S.A. governance

Members of the board: Grifols, S.A.

Manager	Title	Age	Since
Tomás Dagá Gelabert BRD	Director/Board Member	68	2000-04-12
Thomas Heinrich Glanzmann CHM	Chairman	65	2023-02-20
Raimon Grifols Roura BRD	Director/Board Member	61	2001-07-26
Victor Grifols Deu BRD	Director/Board Member	48	2016-05-29
Enriqueta Felip Font BRD	Director/Board Member	59	2019-05-23
Montserrat Muñoz Abellana BRD	Director/Board Member	-	2022-06-09
Susana González Rodríguez BRD	Director/Board Member	47	2022-06-09
Albert Coma-Cros BRD	Director/Board Member	-	2023-12-18
Íñigo Sánchez-Asiaín Mardones BRD	Director/Board Member	59	2015-05-28
Nacho Abia BRD	Director/Board Member	56	2024-02-25

Composition of the Board of Directors

Shareholders: Grifols, S.A.

Name	Equities	%	Valuation
Grifols Roura Family 9.195 %	39,183,692	9.195 %	357 M €
Scranton Enterprises BV 8.404 %	35,812,622	8.404 %	326 M €
Grifols Gras Family 7.089 %	30,209,093	7.089 %	275 M €
Ralledor Holding Spain SL 6.154 %	26,224,374	6.154 %	239 M €
DWS Investment GmbH 3.233 %	13,775,958	3.233 %	125 M €

Name	Equities	%	Valuation
Brandes Investment Partners LP 5.156 %	13,480,174	5.156 %	95 M €
Cobas Asset Management SGIIC SA 1.062 %	2,777,036	1.062 %	20 M €
AzValor Asset Management SGIIC SA 0.6831 %	1,785,916	0.6831 %	13 M €
SIA Funds AG 0.4208 %	1,099,976	0.4208 %	8 M €
Devon Equity Management Ltd. 0.2618 %	684,481	0.2618 %	5 M €

Name	Equities	%	Valuation
Capital Research & Management Co. (World Investors) 8.025 %	20,979,872	8.025 %	147 M €
Brandes Investment Partners LP 7.614 %	19,903,997	7.614 %	139 M €
Permian Investment Partners LP 4.718 %	12,333,499	4.718 %	86 M €
Black Creek Investment Management, Inc. 4.250 %	11,110,345	4.250 %	78 M €
Millennium Management LLC 4.104 %	10,729,530	4.104 %	75 M €

Name	Equities	%	Valuation
Yousif Capital Management LLC 0.001549 %	13,202	0.001549 %	60 069 €

List of GRIFOLS, S.A. shareholders

Holdings: Grifols, S.A.

Name	Equities	%	Valuation
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. 6.49%	437,069,656	6.49%	454,408,209 $

Company details: Grifols, S.A.

Grifols SA

Avinguda de la Generalitat, 152-158 Parc de Negocis Can Sant Joan

08174, Barcelona

+34 935 712 200

http://www.grifols.com

Group companies: Grifols, S.A.

Name	Category and Sector
Gri-Cel SA Gri-Cel SA Financial ConglomeratesFinance Part of Grifols SA, Gri-Cel SA is a Spanish company that provides investment services. The company is based in Barcelona, Spain. The CEO of the company is Dirk Büscher.	Financial Conglomerates
Grifols India Healthcare Pvt Ltd.
Squadron Reinsurance DAC Squadron Reinsurance DAC Multi-Line InsuranceFinance Part of Grifols SA, Squadron Reinsurance DAC is an Irish company that provides reinsurance services. The company is based in Dublin, Ireland.	Multi-Line Insurance

See all subsidiaries

Biopharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GRIFOLS, S.A.	+8.46%	+9.62%	-31.21%	-38.89%	5.75B
CSL LIMITED	-0.45%	-1.19%	+3.28%	-6.37%	86.2B
SAMSUNG BIOLOGICS CO.,LTD.	-1.04%	-1.25%	+34.99%	+5.33%	47.24B
UCB	+1.72%	-1.19%	+136.13%	+84.75%	35.8B
BIOGEN INC.	+0.73%	-2.15%	-36.02%	-32.31%	22.94B
INCYTE CORPORATION	+0.01%	-2.85%	+27.09%	+10.84%	13.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-0.82%	-1.27%	+57.39%	-37.62%	13.25B
BIOMARIN PHARMACEUTICAL INC.	-0.69%	-0.81%	-29.44%	-22.29%	12.57B
ALTEOGEN INC.	-3.14%	-3.14%	+323.66%	+324.34%	11.48B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	+0.30%	+4.42%	-53.26%	-64.63%	9.89B
Average	+0.51%	-0.50%	+43.26%	+22.31%	25.91B
Weighted average by Cap.	-0.05%	-1.37%	+37.67%	+16.32%